GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
30 Oct 2018 02:30 PM
RNS
ViiV: positive data for long-acting injectable
29 Oct 2018 10:00 AM
RNS
ViiV - three-year data for long-acting injectable
18 Oct 2018 04:00 PM
RNS
ViiV submits HIV 2DR regulatory application to FDA
18 Oct 2018 09:34 AM
RNS
Director/PDMR Shareholding
17 Oct 2018 05:56 PM
RNS
Director/PDMR Shareholding
17 Oct 2018 05:50 PM
RNS
Director/PDMR Shareholding
17 Oct 2018 11:30 AM
RNS
Director/PDMR Shareholding
16 Oct 2018 04:53 PM
RNS
Director/PDMR Shareholding
16 Oct 2018 09:30 AM
RNS
Director/PDMR Shareholding
16 Oct 2018 09:30 AM
RNS
Director/PDMR Shareholding
10 Oct 2018 03:30 PM
RNS
Director/PDMR Shareholding
01 Oct 2018 01:58 PM
RNS
Total Voting Rights
27 Sep 2018 04:35 PM
RNS
Director/PDMR Shareholding
21 Sep 2018 12:30 PM
RNS
CHMP recommends expansion of Trelegy COPD label
14 Sep 2018 09:00 AM
RNS
ViiV submits HIV 2DR regulatory application to EMA
12 Sep 2018 05:43 PM
RNS
Director/PDMR Shareholding
10 Sep 2018 08:00 AM
RNS
New analysis on efficacy of anti-IL5 biologics SEA
10 Sep 2018 07:00 AM
RNS
GSK receives CRL from FDA for mepolizumab in COPD
07 Sep 2018 02:24 PM
RNS
Director/PDMR Shareholding
07 Sep 2018 02:18 PM
RNS
Director/PDMR Shareholding
03 Sep 2018 05:00 PM
RNS
Total Voting Rights
30 Aug 2018 05:12 PM
RNS
GSK publishes Q4 2018 Dividend Dates
30 Aug 2018 08:12 AM
RNS
EU approve Nucala in severe asthma in children
24 Aug 2018 10:16 AM
RNS
Director/PDMR Shareholding
15 Aug 2018 07:00 AM
RNS
Positive headline results for ViiV HC ATLAS study
10 Aug 2018 03:00 PM
RNS
Director/PDMR Shareholding
08 Aug 2018 12:35 PM
RNS
Director/PDMR Shareholding
07 Aug 2018 07:00 AM
RNS
Iain Mackay appointed GSK Chief Financial Officer
02 Aug 2018 11:04 AM
RNS
Total Voting Rights
31 Jul 2018 05:03 PM
RNS
Director/PDMR Shareholding
31 Jul 2018 04:37 PM
RNS
Director/PDMR Shareholding
27 Jul 2018 04:30 PM
RNS
Director/PDMR Shareholding
27 Jul 2018 02:47 PM
RNS
CHMP recommend Nucala for severe asthma children
26 Jul 2018 07:00 AM
RNS
GSK reports on FDA Ad Com on mepolizumab for COPD
25 Jul 2018 04:15 PM
RNS
Director/PDMR Shareholding
25 Jul 2018 11:00 AM
RNS
GSK and 23andMe Agreement
25 Jul 2018 11:00 AM
RNS
2nd Quarter Results
24 Jul 2018 09:01 AM
RNS
ViiV announces Juluca 100 week data at AIDS 2018
24 Jul 2018 09:00 AM
RNS
ViiV shows positive phIII data on two-drug combo
19 Jul 2018 04:45 PM
RNS
Director/PDMR Shareholding
17 Jul 2018 05:46 PM
RNS
Director/PDMR Shareholding
17 Jul 2018 04:54 PM
RNS
Director/PDMR Shareholding
17 Jul 2018 04:49 PM
RNS
Director/PDMR Shareholding
16 Jul 2018 02:51 PM
RNS
Director/PDMR Shareholding
16 Jul 2018 11:11 AM
RNS
Director/PDMR Shareholding
13 Jul 2018 04:16 PM
RNS
Director/PDMR Shareholding
13 Jul 2018 04:16 PM
RNS
Director/PDMR Shareholding
11 Jul 2018 02:42 PM
RNS
Director/PDMR Shareholding
02 Jul 2018 02:30 PM
RNS
Total Voting Rights
14 Jun 2018 07:00 AM
RNS
Positive headline results for ViiV GEMINI studies

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

GSK share price launched at 346p in 1989. 

UK 100

Latest directors dealings